SuperworthInhibikase Therapeutics shares outstanding IKT
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 174.6M
- On a year earlier
- +93.9%
- more shares
Inhibikase Therapeutics had 174.6M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 93.9% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 123.4M | +1908% |
| FY2023 | 6.1M | +45% |
| FY2022 | 4.2M | +1% |
| FY2021 | 4.2M | +204% |
| FY2020 | 1.4M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 174.6M | +94% | |
| Q1 FY26 | 172.3M | +92% | |
| Q4 FY25 | 123.4M | n/a | |
| Q3 FY25 | 90.1M | +914% | |
| Q2 FY25 | 90M | +1094% | |
| Q1 FY25 | 89.5M | +1312% | |
| Q3 FY24 | 8.9M | +66% | |
| Q2 FY24 | 7.5M | +44% | |
| Q1 FY24 | 6.3M | +38% | |
| Q4 FY23 | 6.1M | +45% | |
| Q3 FY23 | 5.3M | +26% | |
| Q2 FY23 | 5.2M | +24% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Inhibikase Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.